Recent advances in Parkinson's disease.
Vécsei
László
L
Szegedi Tudományegyetem, Szent-Györgyi Albert Orvosi és Gyógyszerészeti Centrum, Altalános Orvostudományi Kar, Neurológiai Klinika, H-6725 Szeged, Semmelweis u. 6. vecsei@nepsy.szote.u-szeged.hu
D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012642:Selegiline / Q000494:pharmacology* / Q000627:therapeutic use
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D012642:Selegiline; D007980:Levodopa; D004298:Dopamine